You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

Displaying 1 - 10 of 4371 results
  1. Developing Active Stimulation and Monitoring Technologies to Optimize Pain and Nociception Management During Regional Anesthesia, General Anesthesia, and Post-Operative Care

    SBC: PASCALL Systems, Incorporated            Topic: 106

    Project Summary Surgery and acute post-operative pain are major contributors to persistent pain, chronic pain, and opioid dependence. Currently, there are no products on the market in the United States that can be used to monitor surgical nociception. Existing products use indicators that are susceptible to intraoperative influences such as blood loss, anesthetic drugs and antihypertensives. This ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  2. Controlled Gradient Release of Biologics: Enhanced Nerve Conduit for Long‐Gap Injury Repair

    SBC: Pioneer Neurotech Inc.            Topic: 106

    Project Summary / Abstract Nerve injuries arising from trauma, disease, or as a surgical necessity, lead most often to permanent loss of some or all functions mediated by the injured nerves. 50,000 peripheral nerve procedures are performed every year in the US, and 300,000 across Europe. After complete transection of a nerve, the optimal clinical procedure for nerve repair remains the surgical end ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  3. Lipid Receptor GPR31 as a Target for Anti-Thrombotic and Stroke Therapy

    SBC: OASIS PHARMACEUTICALS, LLC            Topic: NHLBI

    Despite prevalent use of anti-platelet and anti-lipid therapies, stroke remains the third major cause of death and is the leading cause of adult disability in the US with an estimated cost in the range of $34 billion annually. Approximately 20% of the annual 795,000 stroke patients die within one year and 15-30% are permanently disabled. Antiplatelet therapy is mainly used for primary prevention o ...

    STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  4. Developing a virtual reality guided acupuncture imagery treatment for Chronic low back pain

    SBC: MASSACHUSETTS NEURO TECHNOLOGY, INC.            Topic: NCCIH

    Project Summary Low back pain (LBP) is one of the most common reasons for physician visits in the USA. A substantial number of chronic LBP (cLBP) patients do not adequately respond to current treatment options. Thus, the development of new treatments for cLBP is urgently needed. The use of imagery to treat illness, including chronic pain, is one of the oldest medical practices. Although still unde ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  5. Development of an Orally Available Therapeutic for Neutralizing C. difficile Toxin B

    SBC: NECTAGEN INC            Topic: NIAID

    Infection with the bacterium C. difficile is the most common and increasingly prevalent cause of diarrhea. In the United States, cases of C. difficile infection (CDI) are estimated to number 500,000 annually and to result in an estimated 15,000 to 30,000 deaths. The cost of these cases is thought to exceed $4.8 billion annually. CDI continues to cause discomfort, serious illness and sometimes deat ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  6. Targeting glioblastoma with CM93, a novel EGFR inhibitor with exceptional brain penetration

    SBC: CRIMSON BIOPHARM INC            Topic: NCI

    PROJECT SUMMARY The epidermal growth factor receptor (EGFR) gene is mutated and/or amplified in majority of primary glioblastoma (GBM). While EGFR-mutant GBM cancer cells are dependent on EGFR signaling for survival, numerous small molecule EGFR tyrosine kinase inhibitors (TKIs) have failed to show efficacy in this disease. There are two main reasons for these failures: i) Many of these EGFR-TKIs ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  7. MTI-301 a SCD1 inhibitor for the treatment of NASH

    SBC: MODULATION THERAPEUTICS, INC.            Topic: 300

    Abstract: Non-alcoholic fatty liver disease (NAFLD) is one of the most common liver diseases in children and adults associated with diet-associated hepatic lipid accumulation (steatosis), and is a common hepatic manifestation of obesity and metabolic syndromes including diabetes. Modulation Therapeutics is developing a stearoyl- coenzyme A desaturase-1 (SCD1) inhibitor for the treatment of NAFLD a ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  8. Developing of a computer-based multimodal mind and body approach for mild cognitive decline

    SBC: BRAIN THRIVE TECHNOLOGY LLC            Topic: NIA

    Summary Mild cognitive impairment (MCI) represents an intermediate state between normal aging and the diagnosis of clinically probable very early Alzheimer's disease (AD). Since MCI manifests before the onset of AD, it may be the optimal stage in which to intervene with preventative therapies for AD and age-related dementia before progressive neurological loss and irreversible cognitive impairment ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  9. Translational development of novel CRISPR approach to treat genomic duplications

    SBC: MYOFINITY BIOSCIENCES INC            Topic: NIAMS

    PROJECT ABSTRACT The goal of this Phase I STTR project is to accomplish key milestones in commercializing a novel SaCas9 nickase-based system (CRD-002) to treat dystrophinopathies in order to restore the production of healthy, endogenous full-length dystrophin protein otherwise compromised by duplication mutations. Duchenne muscular dystrophy (DMD) is characterized by progressive muscle loss and c ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  10. Exploiting translation elongation for improved biologics manufacturing

    SBC: CODOMAX INC.            Topic: NCATS

    Abstract – Codomax has developed a codon engineering platform that enables bespoke, high-yield, cost- effective protein manufacturing by leveraging a newly discovered translational regulatory system in industrially relevant cell systems. Protein manufacturing has a current estimated market size of over $300 billion, distributed among the areas of antibodies and biologic therapeutics, biotechnolo ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government